Maxim Group Starts ContraFect Corporation (CFRXU) at Buy
Get Alerts CFRXU Hot Sheet
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Maxim Group initiates coverage on ContraFect Corporation (NASDAQ: CFRXU) with a Buy rating and a price target of $16.00.
Analyst Jason Kolbert comments, "ContraFect is developing a novel therapy (CF-301) for severe blood infections that often progress to septic shock by utilizing lysins that can digest or lyse a bacterium (cell wall) on contact. If successful, lysins could create a paradigm shift in anti-infectives as a new class of antibiotics is born."
He added, "ContraFect's IND was placed on clinical hold shortly after it was filed in 1Q13, with the FDA requesting additional pre-clinical studies. Those studies are now complete, and management expects to meet with the FDA by year-end. ContraFect should be in a position to initiate trials by early 2015. The lifting of the clinical hold represents a catalyst for shareholders."
"Moving beyond Tamiflu: CF-404 is a universal antibody platform for the treatment of influenza that extends the treatment window beyond Tamiflu. An IND filing is expected by year-end 2015."
For an analyst ratings summary and ratings history on ContraFect Corporation click here. For more ratings news on ContraFect Corporation click here.
Shares of ContraFect Corporation closed at $5.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Grindr (GRND) at Buy
- William Blair Starts Bentley Systems Inc. (BSY) at Outperform, 'believe the company has several growth levers'
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
Create E-mail Alert Related Categories
Analyst Comments, FDA, Hot New Coverage, New CoverageRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!